TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25872890

Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional radical hysterectomy (CRH)
Number of subjects: 86
Study: 24088835

Group type: EXPERIMENTAL
Intervention: Resin composite crowns with fiber-reinforced framework
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Resin composite crowns without fiber-reinforced framework
Number of subjects: 66

Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 66
Study: 21461891

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (800 mg) in fasting state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brivanib alaninate (800 mg) following ingestion of a high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivanib alaninate (800 mg) once daily until discontinuation (multiple doses)
Number of subjects: 0
Study: 19158659

Group type: EXPERIMENTAL
Intervention: Training arm and hand together
Number of subjects: 8

Group type: COMPARATOR
Intervention: Training arm and hand separately
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Virtual mirror feedback
Number of subjects: 8
Study: 17370489

Group type: EXPERIMENTAL
Intervention: Needle-pricking therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Medication (domiphen and HCG)
Number of subjects: 121
Study: 15548313

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 108

Group type: COMPARATOR
Intervention: artesunate-mefloquine
Number of subjects: 108
Study: 11837987

Group type: EXPERIMENTAL
Intervention: Folic acid, alone or in combination with vitamin B12 and vitamin B6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9522322

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (100 IU/day) with calcium supplementation (1000 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcium supplementation (1000 mg/day) with placebo intranasal spray
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (100 IU/day)
Number of subjects: 38
Study: 8425809

Group type: EXPERIMENTAL
Intervention: Topical clindamycin lotion applied twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oral tetracycline (250 mg four times a day for 3 weeks, then 250 mg twice a day for the remaining 9 weeks)
Number of subjects: 43
Study: 3675694

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1000 mg + ambroxol 60 mg t.i.d. (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amoxicillin 1000 mg t.i.d. (n = 8)
Number of subjects: 16
Study: 2649400

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gentamicin/Metronidazole
Number of subjects: 100
Study: 4950563

Group type: EXPERIMENTAL
Intervention: Cholera vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typhoid vaccine (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unvaccinated group
Number of subjects: 0
Study: 31401085

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Zidovudine (AZT)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Body weight <48 kg
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Body weight 48-59.9 kg
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 640
Study: 28362032

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided blocks (U group)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Peripheral nerve stimulator-confirmed blocks (N group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided and peripheral nerve stimulator-confirmed blocks (dual guidance; NU group)
Number of subjects: 109
Study: 25308804

Group type: EXPERIMENTAL
Intervention: Longer and stronger post-induction therapy for T cell ME WBC patients
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard treatment for B-ALL ME WBC patients
Number of subjects: 251

Group type: COMPARATOR
Intervention: Standard treatment for patients with WBC <200 × 10(9) /l
Number of subjects: 251
Study: 23058230

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 21666574

Group type: EXPERIMENTAL
Intervention: Group rehabilitation (GrpR) for 15 days (T1) followed by individual rehabilitation (IndR) for 15 days (T2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Individual rehabilitation (IndR) for 15 days (T1) followed by group rehabilitation (GrpR) for 15 days (T2)
Number of subjects: 27
Study: 20082252

Group type: EXPERIMENTAL
Intervention: Warming moxibustion on Shenque acupoint (RN8)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Smecta (control group)
Number of subjects: 60
Study: 17416007

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) plus Ginsenosides (GS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ginsenosides (GS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15610309

Group type: EXPERIMENTAL
Intervention: lamivudine and IFN-alpha (LAM/IFN)
Number of subjects: 83

Group type: COMPARATOR
Intervention: lamivudine only (LAM)
Number of subjects: 83
Study: 11502614

Group type: EXPERIMENTAL
Intervention: Patient Education (PE) - 7 x 30 minute one to one sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard management (Control Group)
Number of subjects: 100
Study: 9229231

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (NNS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Smoking four cigarettes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study: 8389406

Group type: EXPERIMENTAL
Intervention: Liquid diet with soluble fiber (21 g/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Liquid diet without soluble fiber
Number of subjects: 12

Group type: COMPARATOR
Intervention: Self-selected diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both liquid diets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fasting cholecystokinin concentrations
Number of subjects: 12
Study: 2831114

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily, doubled if BP not controlled after 4 weeks
Number of subjects: 174

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg once daily, doubled if BP not controlled after 4 weeks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 174

Group type: COMPARATOR
Intervention: HCTZ
Number of subjects: 174
Study: 30903459

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH), Fraxiparine (0.4 ml, 3800 IU/day) for 2 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg/day for 2 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 20 mg/day for 2 days
Number of subjects: 74
Study: 28356142

Group type: EXPERIMENTAL
Intervention: 10 μg (400 IU) of vitamin D3 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 μg (1200 IU) of vitamin D3 supplementation
Number of subjects: 0
Study: 27004303

Group type: EXPERIMENTAL
Intervention: Propofol TCI
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 75

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 75
Study: 23291602

Group type: EXPERIMENTAL
Intervention: Assistive technology intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 44
Study: 20473229

Group type: EXPERIMENTAL
Intervention: Trekking poles (TP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No poles (NP)
Number of subjects: 37
Study: 18275558

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16489972

Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (UC) using a conventional home glucose meter
Number of subjects: 200
Study: 14640934

Group type: EXPERIMENTAL
Intervention: 17 alpha‐progesterone caproate (17P) 250 mg/week i.m.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10335904

Group type: EXPERIMENTAL
Intervention: Deflazacort (D)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Prednisone (PN)
Number of subjects: 33
Study: 8747267

Group type: EXPERIMENTAL
Intervention: Spinal fusion for degenerative lumbar disorders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal fusion for recurrent disc herniation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal fusion for spinal stenosis and spondylolisthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal fusion for facet joint syndrome, discogenic pain, and lumbar spondylosis
Number of subjects: 0
Study: 1826544

Group type: EXPERIMENTAL
Intervention: Integrated approach (equal attention to somatic, psychological, dietary, environmental, and physiotherapeutic factors; laparoscopy not routinely performed)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard approach (organic causes excluded first, routine diagnostic laparoscopy performed)
Number of subjects: 106
Study: 6758831

Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Terbutaline 250 micrograms
Number of subjects: 12
Study: 31397369

Group type: EXPERIMENTAL
Intervention: Standard medical treatment and human albumin (HA) infusions (40 g twice weekly for the first 2 weeks, then 40 g weekly for up to 18 months)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Standard medical treatment (SMT) alone
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Standard medical treatment and human albumin (HA) infusions
Number of subjects: 431
Study: 26589186

Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai portoenterostomy (LP group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Open Kasai portoenterostomy (OP group)
Number of subjects: 95
Study: 24508841

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with gemcitabine and carboplatin (GC)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Placebo with gemcitabine and carboplatin (GC)
Number of subjects: 484
Study: 22897339

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Complex fractionated electrograms (CFAE) alone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Combined PVI + CFAE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Use of antiarrhythmic drug (AAD) in the first 3 months postablation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of ERAT
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Increased left atrium size
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Use of AAD in the first 3 months postablation
Number of subjects: 100
Study: 20493783

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS‐MPH) at doses of 18, 36, or 54 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (OROS‐MPH)
Number of subjects: 33
Study: 18375779

Group type: EXPERIMENTAL
Intervention: Promotores-led diabetes self-management education and follow-up
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual diabetic care (wait-list control group)
Number of subjects: 131
Study: 16002810

Group type: EXPERIMENTAL
Intervention: High-DHA algal oil (approximately 200 mg DHA/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vegetable oil (no DHA)
Number of subjects: 0
Study: 12435860

Group type: EXPERIMENTAL
Intervention: rhEPO (3.3 X 10(4) IU/50 ml/30 min) once daily for the first 3 days after stroke
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: rhEPO administered within 5 hours of symptom onset
Number of subjects: 53

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 53
Study: 9793962

Group type: EXPERIMENTAL
Intervention: Permanent histological sections obtained from prostate carcinoma material processed from fine needle aspirates.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunocytochemistry (ICC) procedures applied to tumor sections.
Number of subjects: 0
Study: 7894455

Group type: EXPERIMENTAL
Intervention: ChEAT scores
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Desire to lose weight
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Weight-losing behaviors
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: At-risk index by gender
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Preoccupation with thinness and weight-losing behaviors
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: DDQ items
Number of subjects: 476
Study: 2673316

Group type: EXPERIMENTAL
Intervention: Nicardipine 60 mg twice daily for 4 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 11
Study: 327942

Group type: EXPERIMENTAL
Intervention: Beclomethasone aerosol given intranasally for 3 weeks (active drug)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo for 3 weeks (control)
Number of subjects: 44
Study: 30916450

Group type: EXPERIMENTAL
Intervention: Multi-strategic memory training (MMT) - 10 weekly 90-min sessions
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Multi-strategic memory training (MMT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 201
Study: 27789170

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Postintervention minimum lumen area (MLA) at the target lesion
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: MLA/distal reference segment lumen area ratio
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: MLA < 5.0 mm2
Number of subjects: 804
Study: 26105531

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) treatment following accidental dural puncture (ADP)
Number of subjects: 60
Study: 22496352

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) - either nicotine patch or nicotine gum for 5 weeks
Number of subjects: 6261

Group type: COMPARATOR
Intervention: No intervention cohort
Number of subjects: 6261
Study: 21752257

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (20 sessions over 30 weeks)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Short Term Psychoanalytic Therapy (30 sessions over 30 weeks)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Specialist Clinical Care (12 sessions over 20 weeks)
Number of subjects: 540
Study: 19174696

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily with compliance-enhancing program
Number of subjects: 8108

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg daily without compliance-enhancing program
Number of subjects: 8108

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily with compliance-enhancing program in statin-naive patients
Number of subjects: 8108

Group type: COMPARATOR
Intervention: rosuvastatin 10 mg daily without compliance-enhancing program in statin-naive patients
Number of subjects: 8108
Study: 17096684

Group type: COMPARATOR
Intervention: Mizoribine 12 mg kg(‐1) day(‐1) (multiple-dose study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mizoribine 3, 6, 9, and 12 mg kg(‐1) (single-dose study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mizoribine 6 mg kg(‐1) day(‐1) once daily for 5 days (multiple-dose study)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mizoribine 12 mg kg(‐1) day(‐1) twice daily for 7 days (multiple-dose study)
Number of subjects: 48
Study: 15050853

Group type: EXPERIMENTAL
Intervention: Baby‐Friendly hospital Initiative training programs
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4614
Study: 11696472

Group type: EXPERIMENTAL
Intervention: Intracoronary NO synthase inhibition with N(G)‐monomethyl‐L‐arginine (L‐NMMA; 25 micromol/min)
Number of subjects: 18
Study: 9400037

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 7781205

Group type: EXPERIMENTAL
Intervention: L-arginine (160 mumol/min i.v. for 3 hours)
Number of subjects: 18
Study: 2223361

Group type: EXPERIMENTAL
Intervention: Extradural administration of methadone 5 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 42
Study: 666305

Group type: EXPERIMENTAL
Intervention: Cefadroxil (15 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 50
Study: 29614887

Group type: EXPERIMENTAL
Intervention: SOVT posture during Vocal Function Exercises (VFEs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vowel /o/ during Vocal Function Exercises (VFEs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vowel /a/ during Vocal Function Exercises (VFEs)
Number of subjects: 26
Study: 27909781

Group type: EXPERIMENTAL
Intervention: Low-magnitude mechanical stimulation (LMMS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24661390

Group type: EXPERIMENTAL
Intervention: iVAPS
Number of subjects: 18

Group type: COMPARATOR
Intervention: standard PS
Number of subjects: 18
Study: 22659702

Group type: EXPERIMENTAL
Intervention: IOTN training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ICON training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 21197490

Group type: EXPERIMENTAL
Intervention: Group-bar (splinted mini-implants with a prefabricated bar)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group-ball (two single ball-type mini-implants)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group-ball
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group-bar
Number of subjects: 45
Study: 18544286

Group type: EXPERIMENTAL
Intervention: Imagery stress reduction program
Number of subjects: 34
Study: 15668556

Group type: EXPERIMENTAL
Intervention: Local corticosteroid injection (40 mg of methylprednisolone acetate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iontophoresis of dexamethasone sodium phosphate
Number of subjects: 30
Study: 14506619

Group type: EXPERIMENTAL
Intervention: MgC-Cre (Magnesium-creatine chelate) at 800 mg Mg and 5 g Cre per day for 2 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MgO-Cre (Magnesium oxide plus creatine) at 800 mg Mg and 5 g Cre per day for 2 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Maltodextrin (Placebo)
Number of subjects: 35
Study: 10382900

Group type: EXPERIMENTAL
Intervention: Dirithromycin (two 250 mg tablets od)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline alone (control phase)
Number of subjects: 12
Study: 8525439

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Open (laparotomic) cholecystectomy
Number of subjects: 25
Study: 2407808

Group type: EXPERIMENTAL
Intervention: IRS-I (1972 to 1978)
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: IRS-II (1978 to 1984)
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Group III tumors
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Clinical group I (localized disease, completely resected)
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Clinical group II
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Clinical group III
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Clinical group IV (metastatic disease)
Number of subjects: 1688

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 1688
Study: 6985742

Group type: EXPERIMENTAL
Intervention: iopronic acid (4.5 g)
Number of subjects: 260

Group type: COMPARATOR
Intervention: iopanoic acid (3.0 g)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: iopronic acid
Number of subjects: 260

Group type: COMPARATOR
Intervention: iopanoic acid
Number of subjects: 260
Study: 31874525

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant HIPEC
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard systemic chemotherapy
Number of subjects: 91
Study: 28291050

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study: 25596472

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1mg/kg)
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study: 23959510

Group type: EXPERIMENTAL
Intervention: Array SA40N (AMO, Irvine, CA, USA)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: SA60D3 ReSTOR (Alcon, Fort Worth, TX, USA)
Number of subjects: 229

Group type: COMPARATOR
Intervention: MA60AC (Alcon, Fort Worth, TX, USA)
Number of subjects: 229
Study: 21349488

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with low MVPA (16 hours/week)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with moderate MVPA (35 hours/week)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels with high MVPA (64 hours/week)
Number of subjects: 200
Study: 18835437

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine with psychological stress
Number of subjects: 59

Group type: COMPARATOR
Intervention: Typhoid vaccine with rest
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Saline placebo with psychological stress
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saline placebo with rest
Number of subjects: 59
Study: 17920287

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 22

Group type: COMPARATOR
Intervention: Switch from enoxaparin to UFH
Number of subjects: 22
Study: 15534166

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2231

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 2231
Study: 11181804

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with dextrose alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis with dextrose and amino acids
Number of subjects: 18

Group type: COMPARATOR
Intervention: Time controls (baseline state)
Number of subjects: 18
Study: 9562302

Group type: EXPERIMENTAL
Intervention: Granule cell dispersion (GCD) observed in hippocampal specimens
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Presence of GCD
Number of subjects: 22